Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
Emory University
University of Nebraska
Barbara Ann Karmanos Cancer Institute
Fred Hutchinson Cancer Center
University of Washington
California Cancer Assocaties for Research & Excellence
Medical University of Vienna